Please use this identifier to cite or link to this item:
Title: Accelerated Leukemogenesis by Truncated CBFβ-SMMHC Defective in High-Affinity Binding with RUNX1
Authors: Kamikubo, Y.
Zhao, L.
Hyde, R.K.
Kundu, M.
Compton, S.
Liu, P.P.
Garrett, L.
Wunderlich, M.
Mulloy, J.C.
Corpora, T.
Wolff, L.
Bushweller, J.
Paul, T.A.
Huang, G.
Ito, Y. 
Issue Date: 2010
Citation: Kamikubo, Y., Zhao, L., Hyde, R.K., Kundu, M., Compton, S., Liu, P.P., Garrett, L., Wunderlich, M., Mulloy, J.C., Corpora, T., Wolff, L., Bushweller, J., Paul, T.A., Huang, G., Ito, Y. (2010). Accelerated Leukemogenesis by Truncated CBFβ-SMMHC Defective in High-Affinity Binding with RUNX1. Cancer Cell 17 (5) : 455-468. ScholarBank@NUS Repository.
Abstract: Dominant RUNX1 inhibition has been proposed as a common pathway for CBF leukemia. CBFβ-SMMHC, a fusion protein in human acute myeloid leukemia (AML), dominantly inhibits RUNX1 largely through its RUNX1 high-affinity binding domain (HABD). However, the type I CBFβ-SMMHC fusion in AML patients lacks HABD. Here, we report that the type I CBFβ-SMMHC protein binds RUNX1 inefficiently. Knockin mice expressing CBFβ-SMMHC with a HABD deletion developed leukemia quickly, even though hematopoietic defects associated with Runx1-inhibition were partially rescued. A larger pool of leukemia-initiating cells, increased MN1 expression, and retention of RUNX1 phosphorylation are potential mechanisms for accelerated leukemia development in these mice. Our data suggest that RUNX1 dominant inhibition may not be a critical step for leukemogenesis by CBFβ-SMMHC. © 2010 Elsevier Inc. All rights reserved.
Source Title: Cancer Cell
ISSN: 15356108
DOI: 10.1016/j.ccr.2010.03.022
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.


checked on May 23, 2022


checked on May 23, 2022

Page view(s)

checked on May 12, 2022

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.